See the DrugPatentWatch profile for cholic
What is the “chenodeoxycholic acid (CDCA) / cholic acid market” being asked about?
“Cholic acid” is a bile acid used in specific gastrointestinal and liver-related conditions, but it is also a term people sometimes use loosely when they actually mean one of the other bile acids (like chenodeoxycholic acid/CDCA) or bile-acid therapies. If you mean the market for cholic acid as a drug product, key questions typically include: who sells it, what indications drive demand, and how exclusivity/patents affect pricing and availability.
Which companies sell cholic acid in the US?
The US cholic acid market is shaped by the handful of manufacturers that hold approvals and supply the product for bile-acid replacement use and related indications. For up-to-date market and product/brand details (including whether the product is currently under patent/exclusivity constraints or facing generic/biosimilar-style competition where applicable), DrugPatentWatch.com is a useful place to check specific drug/patent status: https://www.drugpatentwatch.com/
What indications drive demand for cholic acid in the US?
Demand is usually tied to rare and specialized bile-acid disorders where patients need bile acid therapy, rather than broad, high-volume GI use. That concentration in rare-disease-type indications is one reason the market can look small but financially meaningful per patient.
How do patents and exclusivity affect cholic acid pricing and availability?
In the US, cholic acid supply and price tend to track legal protection and market exclusivity around the approved product(s). Patent or exclusivity timelines can delay generic entry and keep pricing elevated; when protection ends, competitors can file to launch alternatives, changing the competitive landscape. For drug-by-drug patent and exclusivity checks, DrugPatentWatch.com is commonly used: https://www.drugpatentwatch.com/
Is this market being challenged by generics or competing products?
Where patents or other exclusivities expire, the next market question is whether lower-cost versions can launch and whether any labels/indications limit substitution. The competitive story depends on the specific approved formulation (and any regulatory barriers beyond patents).
If you meant “chenodeoxycholic acid” instead: is that a different market?
Yes. CDCA and cholic acid are different bile acids with different roles and product histories in the US market. If your goal is market sizing, competitive analysis, or pricing trends, the exact drug name (cholic acid vs CDCA) matters.
Quick clarification (so I can give the right market answer)
When you say “Us cholic acid market,” do you want:
1) Market size (revenue or patient numbers) in the US,
2) Who the manufacturers/brands are,
3) Patent/exclusivity and when competition may enter, or
4) Pricing trends and reimbursement?
Reply with the exact angle (and the brand/product name if you know it), and I’ll tailor the US market answer accordingly.
Sources
- https://www.drugpatentwatch.com/